# Capromorelin Research Overview: What Studies Show About This Oral Ghrelin Receptor Agonist > A look at what published animal and veterinary studies actually show about capromorelin, growth hormone, and appetite. - URL: https://www.lifeconverted.com/learn/capromorelin-research-overview-what-studies-show-about-this-oral-ghrelin-recepto - Category: Growth Hormone & Performance - Author: Hana Suzuki, Sleep & Cognition Writer - Published: 2026-11-11 - Reading time: 3 min - Keywords: capromorelin research overview, capromorelin growth hormone, ghrelin receptor agonist research, capromorelin appetite stimulant studies --- Most growth hormone secretagogues you read about in research circles are unapproved compounds sold strictly for lab or self directed study. Capromorelin sits in a different category. It is an FDA approved drug, just not for humans. It is the active ingredient in Entyce, approved for appetite stimulation in dogs, and Elura, approved for the same purpose in cats. That approval status gives capromorelin an unusually deep and well documented research trail, but almost all of it runs through veterinary and animal lab literature rather than human trials. Here is what the published studies actually measured, and where that trail stops. ## What capromorelin is and how it activates the ghrelin receptor Capromorelin is a small molecule, not a peptide, but it belongs to the same functional family as peptide growth hormone secretagogues because it targets the same receptor. Ghrelin is the body's natural hunger hormone, and it works by binding to a receptor on pituitary cells that triggers growth hormone release. Capromorelin was designed to mimic that binding. Taken orally, it crosses into circulation and activates the ghrelin receptor directly, without needing an injection. That dual action, on the ghrelin receptor and downstream on growth hormone output, is why capromorelin shows up in two very different research conversations. One side studies it purely as an appetite drug. The other studies it as a growth hormone secretagogue with metabolic effects that go beyond hunger. A 2024 review walks through this dual identity and summarizes how both lines of evidence developed in parallel over roughly two decades of veterinary pharmacology work ([Rathore et al., 2024](https://pubmed.ncbi.nlm.nih.gov/37493940/)). ## Growth hormone and IGF 1 findings after oral dosing The clearest mechanistic data on growth hormone response comes from a 2024 safety and efficacy study in rhesus macaques, a nonhuman primate model that sits closer to human physiology than rodents or companion animals. Researchers gave oral capromorelin and tracked hormone and metabolic markers over time, reporting measurable growth hormone stimulation alongside a favorable safety profile at the doses tested ([Campellone et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38423529/)). This is one of the few primate data points in the capromorelin literature, and it matters because primate pituitary and receptor biology tends to predict human response more reliably than dog or rodent data. On the metabolic side, a study in healthy dogs looked specifically at glycemic control after capromorelin dosing, since growth hormone secretagogues can influence insulin sensitivity and blood glucose as a downstream effect of elevated growth hormone and IGF 1. The researchers found measurable shifts in glycemic markers, a reminder that activating the ghrelin receptor does not just move the needle on appetite or growth hormone in isolation, it touches glucose handling too ([Pascutti et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35689953/)). That finding lines up with what is already understood about other ghrelin receptor agonists and growth hormone secretagogues more broadly, where transient changes in insulin sensitivity are a known, expected part of the pharmacology rather than a surprise side effect. A separate line of rodent work examined body weight outcomes after enteral capromorelin dosing in mice, giving researchers a controlled, lower cost model to study dose response before moving to larger animals. The study tracked weight gain over the dosing period and offered supporting data on how consistently oral capromorelin produces measurable physiological change across species ([Punger et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39025662/)). ## Appetite stimulation and lean mass research in animals Appetite is where capromorelin has the deepest and most clinically relevant evidence, because it is the basis of its actual veterinary approval. The foundational dog study described capromorelin as a novel ghrelin receptor agonist therapy for appetite stimulation, documenting increased food intake in a controlled trial setting that eventually supported its approval as Entyce ([Rhodes et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29468076/)). The feline side of the research followed a similar arc. A randomized, masked, placebo controlled trial in cats with unintended weight loss found that capromorelin produced measurable weight gain compared to placebo, the kind of trial design that carries real evidentiary weight ([Wofford et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41204815/)). A 2025 review of feline therapeutics places that trial in context alongside other drugs used for weight and appetite management in cats, noting where capromorelin fits among newer veterinary options ([Susi et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41051985/)). Rabbits add another data point. A 2022 study compared capromorelin directly against mirtazapine, a commonly used appetite stimulant in veterinary medicine, measuring food intake in New Zealand White rabbits. The head to head design is useful because it tests capromorelin against an existing standard rather than against placebo alone, giving a clearer sense of relative effect size ([Draper et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35981857/)). None of these studies were designed to isolate lean mass changes as a primary outcome the way a bodybuilding focused human trial might. Weight gain in a cat recovering from unintended weight loss is not the same question as whether a healthy adult gains lean tissue on a secretagogue. That distinction matters when people try to extrapolate appetite stimulant data into performance or physique contexts it was never built to answer. ## How capromorelin compares to macimorelin and other ghrelin receptor agonists Capromorelin and [macimorelin](/peptides/macimorelin) activate the same receptor through a similar binding mechanism, and both are taken orally, which sets them apart from injectable secretagogues like ipamorelin or GHRP2. The difference is in how each drug's research track was built out. Macimorelin's entire approved use is diagnostic, confirming adult growth hormone deficiency in a clinical setting, and its human trial data reflects that narrow purpose. Capromorelin's approved use is appetite stimulation in companion animals, so its trial data reflects dogs, cats, and research animals rather than diagnostic human endpoints. Both compounds still work through the same upstream biology as ghrelin itself, and both produce a pulse of growth hormone release that researchers can measure directly. What differs is which outcomes got funded and published. Macimorelin's literature centers on human endocrine diagnostics. Capromorelin's literature centers on veterinary appetite and metabolic outcomes, with primate and rodent studies filling in some of the mechanistic gaps. Anyone comparing the two compounds should pay attention to this difference in evidence base rather than assuming equivalent human relevance just because the receptor target is shared. ## Research limitations and open questions A few honest gaps stand out across this body of work. First, there is no published controlled human trial measuring capromorelin's effect on growth hormone, IGF 1, or body composition in healthy adults. The approved human relevant secretagogues in this space, like macimorelin, have that data. Capromorelin does not. Second, detection science has started to catch up with use outside its approved context. A 2023 analytical chemistry study developed methods to detect capromorelin in urine after both oral and dermal administration, work typically driven by anti doping or regulatory testing needs in animal sport contexts ([Sobolevsky et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37688359/)). That kind of study tells you capromorelin is already being used outside its labeled appetite stimulant purpose in at least some settings, which is a signal worth taking seriously rather than a reason to extrapolate benefit. Third, the glycemic signal seen in dogs raises a question that has not been fully answered: how does repeated ghrelin receptor activation interact with insulin sensitivity over longer timeframes, and does that interaction look different in species with different baseline metabolic rates. The current literature only offers a short term snapshot. If you are trying to map capromorelin's research against other growth hormone peptides, the [LifeConverted peptide reference library](/all-peptides) organizes compound pages by mechanism so you can compare ghrelin receptor agonists side by side. ## Common questions **Is capromorelin approved for human use?** No. It is FDA approved only as a veterinary drug, sold as Entyce for dogs and Elura for cats, both for appetite stimulation. There is no approved human formulation. **Does capromorelin raise growth hormone the same way as other secretagogues?** Yes, mechanistically. It activates the ghrelin receptor the same way compounds like macimorelin and ipamorelin do, triggering pulsatile growth hormone release from the pituitary. **What is the biggest gap in capromorelin research?** Almost all published data comes from dogs, cats, rabbits, mice, and one primate study. Controlled human trials on growth hormone or body composition outcomes are not part of the current published record. *This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.* ## FAQ ### Is capromorelin approved for human use? No. Capromorelin is FDA approved only as a veterinary drug, sold as Entyce for dogs and Elura for cats, both for appetite stimulation. There is no approved human formulation. ### Does capromorelin raise growth hormone the same way as other secretagogues? Yes, mechanistically. It activates the ghrelin receptor the same way compounds like macimorelin and ipamorelin do, triggering pulsatile growth hormone release from the pituitary. ### What is the biggest gap in capromorelin research? Almost all published data comes from dogs, cats, rabbits, mice, and one primate study. Controlled human trials on growth hormone or body composition outcomes are not part of the current published record. ## Sources - Wofford JA et al., 2025, J Feline Med Surg: https://pubmed.ncbi.nlm.nih.gov/41204815/ - Pascutti KM et al., 2022, Domest Anim Endocrinol: https://pubmed.ncbi.nlm.nih.gov/35689953/ - Rhodes L et al., 2018, Vet Med Sci: https://pubmed.ncbi.nlm.nih.gov/29468076/ - Campellone GA et al., 2024, J Am Assoc Lab Anim Sci: https://pubmed.ncbi.nlm.nih.gov/38423529/ - Draper JM et al., 2022, J Am Assoc Lab Anim Sci: https://pubmed.ncbi.nlm.nih.gov/35981857/ - Punger EM et al., 2024, Comp Med: https://pubmed.ncbi.nlm.nih.gov/39025662/ --- Published by LifeConverted, https://www.lifeconverted.com/learn/capromorelin-research-overview-what-studies-show-about-this-oral-ghrelin-recepto